Metastasectomy Metastatic Melanoma

Rodrigo Arrangoiz MS, MD, FACS, FSSO
  • Despite recent advances in systemic therapy for advanced melanoma:
    • This disease will eventually fail to respond to systemic therapies in the majority of patients with stage IV disease:
      • And surgical resection (metastasectomy) thus remains an important consideration
    • The findings of retrospective series and prospective registries:
      • Have confirmed that long-term survival is possible for a substantial minority of appropriately selected patients who have resection for stage IV disease
    • With appropriate patient selection, metastasectomy:
      • May be the initial preferred modality rather than systemic therapy
    • A history of significant autoimmune disease, such as colitis:
      • Could exclude a patient from consideration of checkpoint blockade drugs:
        • However, metastasectomy would be a reasonable consideration even in patients who are candidates for systemic treatment
  • Appropriate selection of candidates for metastasectomy is crucial:
    • Although solitary metastases are most favorable:
      • The presence of more than one nodule is not an absolute contraindication to resection
      • Selection factors include:
        • The extent of disease:
          • The number of metastases
          • The number of involved sites
        • The tumor growth rate or doubling time
        • The patient’s comorbidities
        • It must be possible to remove all evident disease:
          • As incomplete resection of metastases has not been beneficial in some patients relative to nonsurgical treatment
        • Palliative intent is another potential indication for surgery in stage IV melanoma:
          • But this is not the only indication for surgery
  • References:
    • Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507-2616.
    • Morton DL, Foshag LJ, Hoon DS, et al. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg. 1992;216:463-482.
    • Ollila DW. Complete metastasectomy in patients with stage IV metastatic melanoma. Lancet Oncol. 2006;7:919-924.
    • Sosman JA, Moon J, Tuthill RJ, et al. A phase 2 trial of complete resection for stage IV melanoma: Results of Southwest Oncology Group Clinical Trial S9430. Cancer. 2011;117:4740-4746.

Published by Rodrigo Arrangoiz MS, MD, FACS, FSSO

My name is Rodrigo Arrangoiz I am a breast surgeon/ thyroid surgeon / parathyroid surgeon / head and neck surgeon / surgical oncologist that works at Center for Advanced Surgical Oncology in Miami, Florida. I was trained as a surgeon at Michigan State University from (2005 to 2010) where I was a chief resident in 2010. My surgical oncology and head and neck training was performed at the Fox Chase Cancer Center in Philadelphia from 2010 to 2012. At the same time I underwent a masters in science (Clinical research for health professionals) at the University of Drexel. Through the International Federation of Head and Neck Societies / Memorial Sloan Kettering Cancer Center I performed a two year head and neck surgery and oncology / endocrine fellowship that ended in 2016. Mi nombre es Rodrigo Arrangoiz, soy cirujano oncólogo / cirujano de tumores de cabeza y cuello / cirujano endocrino que trabaja Center for Advanced Surgical Oncology en Miami, Florida. Fui entrenado como cirujano en Michigan State University (2005 a 2010 ) donde fui jefe de residentes en 2010. Mi formación en oncología quirúrgica y e n tumores de cabeza y cuello se realizó en el Fox Chase Cancer Center en Filadelfia de 2010 a 2012. Al mismo tiempo, me sometí a una maestría en ciencias (investigación clínica para profesionales de la salud) en la Universidad de Drexel. A través de la Federación Internacional de Sociedades de Cabeza y Cuello / Memorial Sloan Kettering Cancer Center realicé una sub especialidad en cirugía de cabeza y cuello / cirugia endocrina de dos años que terminó en 2016.

Leave a Reply

Fill in your details below or click an icon to log in:

Gravatar
WordPress.com Logo

You are commenting using your WordPress.com account. ( Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. ( Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. ( Log Out /  Change )

Cancel

Connecting to %s